ENSC earnings analysis
What we found in ENSC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Ensysce reported Q2 2026 federal grant revenue of $1.164 million, down approximately 15.1% from $1.371 million in the prior-year period, while diluted EPS improved to $(0.20) from $(0.79). The $2.571 million net loss shows that substantial operating losses continue despite improved per-share results. The Cy Biopharma acquisition and $38.6 million financing support liquidity, but no numeric revenue or EPS guidance was provided and further runway depends partly on an additional financing tranche.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Grant revenue declined year over year
- Q2 2026 federal grant revenue was $1.164 million, down from $1.371 million in the prior-year period, a decline of approximately 15.1%.
- EPS loss narrowed materially
- Diluted EPS improved to $(0.20) from $(0.79) in Q2 2025 and $(0.52) in Q1 2026.
- Loss remained substantial
- The company reported a Q2 2026 net loss of $2.571 million despite the improvement in diluted EPS.
- Funding position strengthened
- The Cy Biopharma acquisition and a financing of $38.6 million improve the company’s funding position, although the additional financing tranche is subject to completion.
- Runway extends into 2027-2028
- Management indicated cash runway into late 2027, potentially extending into 2028 if the second financing tranche of up to $38.6 million is received.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Persistent operating losses
- The company reported a $2.571 million net loss for Q2 2026, highlighting continued cash-burn and dependence on external financing or non-dilutive funding.
- Financing remains important
- The stated cash runway extends into late 2027, while extension into 2028 depends on receiving a second financing tranche of up to $38.6 million.
- No new risk-factor disclosure
- The 10-Q does not identify new risk-factor changes and refers investors to the risk factors in the 2025 Annual Report; clinical, regulatory and execution risks therefore remain applicable.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.2
- Segment
- Federal grant revenue: $1.164 million
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management previously indicated cash runway into late 2027; a second financing tranche of up to $38.6 million could extend runway into 2028.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 15, 2026
- Ensysce Biosciences reported revenues of $1.88 million for Q4 2026, significantly exceeding estimates by over 276%. EPS was a loss of $0.75, also beating analyst expectations. However, the company continues to incur…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ENSC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever